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Disease-Associated Mutant Ubiquitin Causes
Proteasomal Impairment and Enhances the Toxicity of
Protein Aggregates
Elizabeth M. H. Tank, Heather L. True*
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, United States of America

Abstract
Protein homeostasis is critical for cellular survival and its dysregulation has been implicated in Alzheimer’s disease (AD) and
other neurodegenerative disorders. Despite the growing appreciation of the pathogenic mechanisms involved in familial
forms of AD, much less is known about the sporadic cases. Aggregates found in both familial and sporadic AD often include
proteins other than those typically associated with the disease. One such protein is a mutant form of ubiquitin, UBB+1, a
frameshift product generated by molecular misreading of a wild-type ubiquitin gene. UBB+1 has been associated with
multiple disorders. UBB+1 cannot function as a ubiquitin molecule, and it is itself a substrate for degradation by the
ubiquitin/proteasome system (UPS). Accumulation of UBB+1 impairs the proteasome system and enhances toxic protein
aggregation, ultimately resulting in cell death. Here, we describe a novel model system to investigate how UBB+1 impairs
UPS function and whether it plays a causal role in protein aggregation. We expressed a protein analogous to UBB+1 in yeast
(Ubext) and demonstrated that it caused UPS impairment. Blocking ubiquitination of Ubext or weakening its interactions with
other ubiquitin-processing proteins reduced the UPS impairment. Expression of Ubext altered the conjugation of wild-type
ubiquitin to a UPS substrate. The expression of Ubext markedly enhanced cellular susceptibility to toxic protein aggregates
but, surprisingly, did not induce or alter nontoxic protein aggregates in yeast. Taken together, these results suggest that
Ubext interacts with more than one protein to elicit impairment of the UPS and affect protein aggregate toxicity.
Furthermore, we suggest a model whereby chronic UPS impairment could inflict deleterious consequences on proper
protein aggregate sequestration.
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recognized by the 26S proteasome. A series of events involving E1,
E2 and E3 enzymes are required to attach ubiquitin via its Cterminal glycine residue to the target protein. The formation of
polyubiquitin chains and the process of ubiquitin conjugation to
protein targets displays exquisite specificity, in part by the
multitude of E2 and E3 enzymes. Despite intensive study, the
roles of many components of the UPS remain to be elucidated.
The importance of the UPS in cellular homeostasis is apparent
not only by the redundancy and conservation of the components,
but also by its role in disease [5,6]. The complex interplay between
protein aggregation and UPS function is easily appreciated, yet it
is often difficult to determine the causal nature of the problem.
UPS dysfunction can prevent the degradation of misfolded
proteins, which can lead to aggregation. Conversely, protein
aggregates can be challenging substrates for the UPS and can thus
cause proteasomal impairment [7]. Protein aggregation is a
hallmark of many neurodegenerative disorders [6]. In addition,
mutations in ubiquitin processing enzymes, such as UCHL1 and
Parkin, can lead to inherited forms of neurodegenerative diseases
[8,9]. Furthermore, many protein aggregates associated with
disease show ubiquitin deposition [10], suggesting that dysfunctional UPS activity may contribute to pathogenesis. Understanding the interplay between protein aggregation and clearance is an

Introduction
As technology and medicine further extend the human lifespan,
age-related diseases will become more prevalent. Alzheimer’s
disease (AD) is a neurodegenerative disorder that affects 20 million
people worldwide and is the most common form of late-onset
dementia [1]. The study of genetic mutations that cause early
onset AD has provided insight into some of the factors involved,
but most cases of AD are sporadic and of unknown origin.
Uncovering the risk factors involved in any multi-factorial disease
is challenging but vital for disease treatment and prevention. Many
fundamental pathways, including the ubiquitin proteasome system
(UPS), have been suggested to play a role in AD. Therefore,
investigating the relationship between AD and the UPS could lead
to new therapeutic targets.
The UPS is an evolutionarily conserved pathway that selectively
eliminates short-lived and damaged proteins. A number of cellular
processes, including the cell cycle, stress response, and DNA
repair, require the UPS [2]. Protein degradation by the UPS
involves a series of enzymes that ultimately attach ubiquitin, a
small well-conserved protein, to an internal lysine residue in the
target protein [3–5]. Multiple ubiquitin proteins can be connected
to form a polyubiquitin chain which serves as a degradation signal
PLoS Genetics | www.plosgenetics.org
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proteasome [20]. However, high levels of UBB+1 expression cause
proteasomal impairment [16,21,22]. As a natural inhibitor of the
UPS, UBB+1 could be another example whereby proteasomal
impairment induces protein aggregation. Therefore, UBB+1
might act as a disease modifier. Recently, a UBB+1 transgenic
mouse has been characterized [23]. UBB+1 expression resulted in
constant UPS impairment that caused a minor learning deficit and
caused changes in transcription profiles that mirror those found in
brains of humans with AD [23]. The expression of UBB+1 in
mammalian cells enhances the toxicity and aggregation of an
expanded polyglutamine protein [24]. However, measuring
changes in protein aggregation in cells that are dying from toxic
protein aggregates is challenging. Hence, it remains to be
determined if UBB+1 affects protein aggregation per se, or if it
affects the ability of the cells to cope with the aggregates.
We developed a model system using Saccharomyces cerevisiae to
evaluate the cellular effects of UBB+1. We expressed a mutant
ubiquitin protein (Ubext) analogous to UBB+1 and found that it
caused UPS impairment in yeast. Furthermore, we found that Ubext
changed the ubiquitination pattern on a UPS substrate. Taking
advantage of non-toxic protein aggregates in yeast, we demonstrated
that the expression of Ubext neither induced nor changed these
aggregates. However, Ubext did make cells more susceptible to toxic
protein aggregates. We propose that Ubext does not cause protein
aggregation, but rather acts as a phenotypic enhancer of deleterious
aggregation. We present a model based on our work and other
recent advances in the field to explain how this might occur.

Author Summary
The accumulation of cytotoxic protein aggregates occurs
in many neurodegenerative diseases. It is difficult to
determine if the protein aggregates found in these
diseases represent a cause or consequence of the disorder.
Degradation pathways, such as the ubiquitin/proteasome
system (UPS), remove misfolded proteins that are prone to
aggregate. The UPS involves many players that work in
concert to target proteins for degradation by the
proteasome. A mutant form of ubiquitin has been
associated with many diseases, including Alzheimer’s
disease. We developed a yeast model of the mutant
ubiquitin protein in order to investigate its effect on UPS
function and protein aggregation. We demonstrate that
this mutant ubiquitin causes impairment of the UPS and
suggest that it does so by interacting with multiple
components of the pathway. Using this model, we
evaluated the effects of the mutant ubiquitin on nontoxic
protein aggregates and found that they were unaltered by
its presence. We demonstrate that the mutant ubiquitin
acts as a modifier, which increases cellular susceptibility to
the phenotypic effects of deleterious protein aggregates
by altering UPS functionality and substrate ubiquitination.
Furthermore, the system we developed can be utilized to
further understand the complex interplay of proteasomal
impairment and protein aggregate toxicity.
active area of research, but most systems are complicated by
cellular toxicity, which alone can have negative consequences on
protein homeostasis.
A mutant form of ubiquitin was found associated with AD and
other diseases and was proposed to act as a natural proteasome
inhibitor [11]. The generation of this mutant ubiquitin protein is
unusual - the mutation is found in the messenger RNA, but not in
the DNA sequence of the ubiquitin-B gene. The mutant ubiquitin
results from a dinucleotide deletion near the 39 end of the mRNA
transcript which shifts the reading frame for translation. The
mutant protein has been named UBB+1 [12]. The dinucleotide
deletion event in the mRNA has been termed ‘‘molecular
misreading’’, though the mechanism by which the deletion occurs
remains elusive [13,14]. Many human mRNA transcripts,
including all copies of ubiquitin, contain potential sites for
molecular misreading, since hotspots for these events are
hypothesized to occur near simple repeat sequences (e.g. GAGAG)
[15]. The best characterized +1 mutant ubiquitin protein has a
short C-terminal extension, with the majority of the protein being
identical to ubiquitin [12]. As such, the protein is presumably
folded and recognized as ubiquitin, but the C-terminal glycine
residue essential for conjugation to substrates is absent.
The accumulation of the UBB+1 protein in the neurological
hallmarks of AD is curious, since the mutant cannot be conjugated
to target proteins [12]. The presence of UBB+1 has been proposed
to represent an endogenous readout of proteasomal dysfunction
[16,17]. Due to its association with protein aggregation, it was also
suggested that UBB+1 could contribute to disease pathology [18].
UBB+1 protein accumulation has been documented in multiple
disorders such as polyglutamine expansion diseases (including
Huntington’s disease), Pick’s disease and even non-neuronal tissue
diseases [11,19]. However, the mechanism of UBB+1 action in
these diseases remains unclear.
To evaluate the role of UBB+1 in disease, the effects of ectopic
UBB+1 expression have been investigated in cultured mammalian
cells. Although UBB+1 cannot be conjugated to target substrates,
it can be ubiquitinated by wild type ubiquitin and degraded by the
PLoS Genetics | www.plosgenetics.org

Results
Ubext Expression in Yeast Cannot Functionally Rescue a
Decrease in Wild Type Ubiquitin
The mechanism by which +1 proteins, such as UBB+1, are
produced is currently unknown. To create a yeast model of
UBB+1, we generated an expression vector containing the
sequence of the first ubiquitin-coding region of the yeast tandem
ubiquitin gene, UBI4, such that a dinucleotide deletion occurred
near the carboxy terminus (Figure 1A). The deletion caused a
frameshift in the coding sequence of ubiquitin and extended the
open reading frame to the next stop codon (termed extended
ubiquitin or Ubext). This construct mimics the generation of
UBB+1 from the human tandem ubiquitin gene (ubiquitin-B).
Constitutive expression of Ubext in log-phase yeast did not cause a
growth defect when assessed in either liquid medium (data not
shown) or on solid medium (Figure 1B). Wild type cells expressing
Ubext did show a reduced growth rate after recovery from
stationary phase (data not shown).
To evaluate the functionality of Ubext, we analyzed its ability to
replace wild type ubiquitin. The stress-inducible UBI4 gene
encodes a tandem array of five ubiquitin moieties that are
separated post-translationally by deubiquitinating enzymes (DUBs)
that cleave after the C-terminal glycine residue, G76 [25]. UBI4 is
non-essential in vegetatively growing cells but is required for cells
to recover from various stress conditions [26,27]. We utilized a
strain lacking UBI4 to evaluate the functionality of Ubext. Dubi4
cells were transformed with expression plasmids that contain wild
type ubiquitin, Ubext or empty vector. The transformants were
grown for two weeks to allow them to reach stationary phase and
then plated again to evaluate their ability to recover. Only cells
expressing extra wild type ubiquitin were rescued from the loss of
UBI4 and could grow after this stress (Figure 1C). This
demonstrates that Ubext is a non-functional ubiquitin, as expected
due to the lack of the C-terminal glycine residue required for
conjugation to target substrates.
2
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Figure 1. Ubext does not function as ubiquitin. (A) A schematic diagram depicting the wild type and mutant ubiquitin (Ubext) mRNA and protein
sequences beginning at nucleotide 207 of UBI4. The underlined ATG denotes the beginning of the next ubiquitin open reading frame in the tandem
array. The red triangle signifies the site of the dinucleotide GA deletion. (B) Ubext expression does not affect logarithmically growing yeast. Serial
dilutions of wild type yeast ectopically expressing Ubext, excess wild type ubiquitin (Ub), or an empty vector (EV) control were spotted onto selective
medium. (C) Ubext does not behave as wild type ubiquitin and cannot compensate for the loss of UBI4. The Dubi4 strain was transformed with EV, Ub,
and Ubext. Transformants were plated onto selective medium following growth into stationary phase.
doi:10.1371/journal.pgen.1000382.g001

Ubext Expression Causes UPS Impairment

from the UBI4 promoter using a UBI4promoter-LacZ reporter in
Ubext-expressing cells demonstrated a modest two-fold increase
(data not shown), suggesting that UBI4-induced transcription may
be one, but perhaps not the only source for the increased
ubiquitin. Cells expressing Ubext also displayed an increase in the
abundance of high molecular weight ubiquitin-conjugated proteins
in comparison to the empty vector control (Figure 2B, compare left
lane WT to right lane Ubext). The fact that Ubext caused lethality
in the proteasome mutant strain and Ubext-expressing cells
accumulated ubiquitinated-protein conjugates, suggests that it is
affecting protein degradation. An accumulation of high molecular
weight ubiquitinated proteins also occurred with the over
expression of wild type ubiquitin (Figure 2B, middle lane). Most
likely this occurs because of more ubiquitination of endogenous
proteins due to an excess of functional ubiquitin provided by the
over expression construct.
We tested the functionality of the UPS in cells expressing Ubext
using two different proteasome reporters constructs: an N-end
rule substrate and a ubiquitin fusion degradation (UFD) substrate
[30]. These substrates are processed by the UPS using distinct
enzymes [3,31,32]. The N-end rule substrate is a Ub-R-LacZ
fusion. The ubiquitin moiety is efficiently cleaved by endogenous
DUBs to expose the N-terminal amino acid (arginine) of bgalactosidase (bgal). According to the N-end rule, R-bgal is an
unstable protein that is polyubiquitinated and rapidly degraded
by the 26S proteasome [33]. The UFD reporter substrate is UbP-LacZ. In yeast, no DUB can cleave ubiquitin from bgal if the
first amino acid after ubiquitin is proline. Because of the ubiquitin
fusion, Ub-P-bgal is unstable and is rapidly degraded by the
proteasome. These constructs, along with a stable LacZ control
(Ub-M-LacZ), were transformed into cells expressing Ubext to
assess UPS function by bgal activity assays. Cells expressing Ubext
and either of the unstable proteasome reporters displayed higher
levels of specific bgal activity (Figure 2C and 2D). Cells
expressing extra wild type ubiquitin showed a slight increase in
the stabilization of the reporter constructs. The expression of
extra wild type ubiquitin also generated a large steady state
population of ubiquitin-conjugated proteins (Figure 2B, middle
lane), which could be taxing the degradation capacity of the

If Ubext affects UPS functionality in yeast as UBB+1 does in
mammals, then we hypothesized that Ubext would display
synthetic lethality with a proteasome mutant. We evaluated the
cellular viability of a temperature-sensitive catalytic proteasome
mutant strain (pre1-1 pre2-2) [28] expressing Ubext. As predicted,
Ubext-expressing pre1-1 pre2-2 cells were inviable at the restrictive
temperature (Figure 2A). Wild type cells expressing Ubext grown at
the restrictive temperature did not show a growth defect
(Figure 2A). Next we evaluated another ubiquitination-dependent
process to determine if Ubext effects are more widespread. We
challenged Ubext-expressing cells to DNA damage induced by UV
irradiation and found that they survived as well as the control cells
(data not shown).
Ubext cannot be conjugated to target protein substrates, but
can be recognized as a UPS substrate. Therefore, we assessed its
ubiquitination. Protein lysate from Ubext-expressing cells and
control cells were evaluated by SDS-PAGE and western blot.
Cells expressing Ubext exhibited a unique band which represents
the extended mutant ubiquitin protein (Figure 2B, grey arrow)
which is larger than wild type ubiquitin (Figure 2B, arrowhead).
Cells expressing Ubext also displayed a distinctive laddering
pattern which suggests that Ubext is conjugated by wild type
ubiquitin moieties (Figure 2B, black arrows). A similar laddering
pattern was previously observed in cells expressing UbDGG [29],
a mutant ubiquitin protein lacking only the two C-terminal
glycine residues, and we observed the same pattern when we
expressed UbDGG in yeast (data not shown). Additionally, a
strain lacking the ubiquitin recycling DUB (Dubp14) accumulates
free ubiquitin chains [29] and we also observed that Dubp14 cells
show the same ubiquitin laddering pattern as cells expressing
Ubext (data not shown).
The expression of Ubext also caused an increase in the level of
unconjugated wild type ubiquitin, which was evident by the
accumulation of the mono-ubiquitin band in the Ubext lane in
comparison to the empty vector control lane (Figure 2B, black
arrowhead). Further analysis by quantitative western blot showed
approximately a 10-fold increase in wild type mono-ubiquitin in
the presence of Ubext (data not shown). Transcriptional activity
PLoS Genetics | www.plosgenetics.org
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Figure 2. Expression of Ubext causes proteasomal impairment. (A) Ubext displays synthetic lethality with proteasome mutants. Wild type (WT)
and temperature-sensitive proteasome mutant cells, pre1-1 pre2-2 (11/22), were transformed with plasmids containing empty vector (EV), ubiquitin
(Ub) and Ubext. Serial dilutions of cells were spotted onto selective medium and grown at 30uC and 37uC. (B) Cells expressing Ubext show a distinct
pattern of ubiquitin conjugation. Protein lysate from wild type yeast cells containing an empty vector (WT), extra ubiquitin (Ub OE), or Ubext were
analyzed by SDS-PAGE and western blot using an anti-ubiquitin antibody. Ubext causes an increase in ubiquitin-conjugated proteins (bracket) as
compared to WT. The black arrowhead indicates ubiquitin monomer. The grey arrow points to Ubext. Black arrows represent conjugated Ubext. Pgk1p
expression was probed to assess protein loading on the membrane. (C) Ubext-expressing cells impair the degradation of the N-end rule substrate R-bgalactosidase (bgal). Cells containing EV, Ub, or Ubext were transformed with pGal-Ub-R-LacZ. The stability of R-bgal was measured by specific activity
(luminescence units/mg protein). The asterisk (*) indicates statistical significance between wild type Ub and Ubext (p = 0.0013). (D) Ubext-expression
prevents the efficient proteasomal degradation of a ubiquitin fusion degradation substrate. The stability of Ub-P-LacZ was evaluated as in B. The
asterisk (*) indicates statistical significance between wild type Ub and Ubext (p = 0.0005). (E) Ubiquitinated reporter substrates are present in Ubextexpressing cells. Wild type cells containing the Ub-X-LacZ reporter constructs and expressing Ubext or the control (EV) were analyzed for ubiquitinated
bgal protein. bgal protein was immunoprecipitated with an anti-bgal antibody (left) and the bound fractions were blotted with an anti-ubiquitin
antibody (right). The arrow indicates full length bgal protein.
doi:10.1371/journal.pgen.1000382.g002

proteasome. To evaluate if LacZ fusion expression was affected by
Ubext, stable M-bgal activity was measured and showed no
difference (data not shown). These results demonstrate that the
expression of Ubext in yeast inhibits the degradation of two
different UPS reporter substrates.
Such stabilization of the proteasome reporter constructs could
be due to a lack of ubiquitination of the reporter, since the
expression of Ubext also causes accumulation of unconjugated wild
type ubiquitin. The reporter substrates (bgal protein) were
immunoprecipitated from cells with and without the co-expression
of Ubext. Western blot with an anti-bgal antibody revealed that
more b-gal protein was precipitated in Ubext-expressing cells
(Figure 2E, left). This result correlates with the higher levels of bgal
activity measured in Ubext-expressing cells (Figure 2C and D).
Analysis with an anti-ubiquitin antibody showed ubiquitinconjugated R-bgal and Ub-P-bgal in cells expressing Ubext
(Figure 2E, right). This data demonstrates that Ubext is not
stabilizing these UPS substrates by blocking their ubiquitination.

Simple Modifications Do Not Alleviate the UPS
Impairment Caused by Ubext
We sought to determine how Ubext exerts its negative effects on
the UPS pathway. We asked whether Ubext was sequestrating wild
type ubiquitin proteins. Ubiquitinated-Ubext could be refractory to
DUBs, thereby tying up ubiquitin, as suggested for UBB+1 [20].
To test this hypothesis, we expressed extra ubiquitin in the
presence of Ubext and found that the UPS test substrates were still
stabilized (data not shown). This result was not surprising since
monomeric ubiquitin appears to be abundant in cells expressing
Ubext (Figure 2B, arrowhead). This suggests that a lack of wild type
ubiquitin is not the cause of the UPS impairment elicited by Ubext.
Ubext lacks the essential C-terminal glycine residues (G75 and
G76) required for ubiquitin conjugation and these glycine residues
are vital for many proteins to interact with ubiquitin [40]. We
tested whether adding back two glycine residues to the C-terminal
extension of Ubext (Ubext+GG) could restore these interactions and
alleviate the proteasomal impairment. Cells expressing Ubext+GG
still displayed proteasomal impairment (data not shown), indicating that the C-terminal extension plays a mechanistic role in the
phenotype observed.

Expression of Ubext Does Not Directly Block Proteasome
Function
Another plausible explanation for the UPS inhibition could
be that Ubext binds to the proteasome and this interaction
precludes other proteasome substrates from being efficiently
degraded. Alternatively, Ubext could interact with other
component(s) of the UPS and inhibit their function. To
examine whether Ubext is clogging the proteasome, we took
advantage of a ubiquitin-independent proteasome substrate.
Ornithine decarboxylase (ODC) is an enzyme involved in
polyamine biosynthesis [34,35] and a short peptide from this
protein serves as a ubiquitin-independent degradation signal
(i.e. degron) [36]. Measuring the degradation of ODC reflects
the functionality of the proteasome in a manner independent of
the non-proteasomal components of the UPS cascade. A fusion
of GFP with the degron of ODC (GFP-ODC) serves to target
GFP to the proteasome where it is rapidly degraded [37]. A
point mutation in the ODC degron (C441A) stabilizes the
fusion protein by lowering its affinity for the proteasome
[38,39]. GFP-ODC fusions were transformed into cells
expressing Ubext and the steady state level of GFP-ODC was
evaluated by western blot (Figure 3A). Cells expressing Ubext
were able to degrade the GFP-ODC protein while the stable
GFP-ODCC441A protein accumulated (Figure 3A). Even
prolonged exposure showed that the steady state level of
GFP-ODC was approximately equal with or without Ubext
expression (Figure 3B). Thus, Ubext permits the degradation of
a ubiquitin-independent proteasome substrate, suggesting that
the proteasomal degradation capacity is not significantly
impaired in cells expressing Ubext.
PLoS Genetics | www.plosgenetics.org

Ubext-Ubiquitin Conjugation Is Required for N-End Rule
Substrate Stabilization but not for UFD Substrate
Stabilization
UPS-mediated protein degradation is a selective process and
polyubiquitination is the signal which targets proteins to the
proteasome for degradation [41,42]. Therefore, we asked whether
blocking the ubiquitination of Ubext would alleviate the associated
UPS inhibition. Polyubiquitination can occur on multiple lysine
residues of ubiquitin [43]. We mutated four of the lysine residues
typically utilized for polyubiquitination by changing them to
arginine (referred to as UbextKxR). Ubiquitin conjugation of Ubext
was visualized by a distinct laddering pattern on a western blot
(Figure 2B, black arrows). While none of the single point mutations
prevented ubiquitination of Ubext, the double lysine mutant,
UbextK29/48R, did prevent the conjugation (Figure 4A, black
arrows).
We evaluated the degradation of the UPS substrates in the
presence of the UbextKxR mutants. The expression of each single
UbextKxR mutant stabilized the N-end rule substrate, R-bgal
(Figure 4B). However, the expression of the UbextK29/48R
double mutant allowed for better degradation of the reporter
protein, suggesting that the ubiquitination of Ubext is necessary to
impair the degradation of the N-end rule substrate. The steady
state levels of bgal protein were detected by western blot and
corroborated the result of the bgal activity assay (Figure 4B, lower).
Next, we evaluated the degradation of the UFD substrate in the
presence of the UbextKxR mutants. Each UbextKxR mutant,
5
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Figure 3. Ubext-expressing cells can degrade a ubiquitin-independent substrate. (A) Expression of Ubext does not impair the degradation
of GFP-ODC. Cells containing a stable GFP construct were transformed with empty vector (EV), Ub, or Ubext. These cells were then transformed with
plasmids expressing either GFP-ODC or GFP-ODCC441A. A proteasome mutant strain (pre1-1 pre2-2, abbreviated 11/22) was transformed with both the
GFP and GFP-ODC constructs and as expected, both were stable. Protein lysates were separated by SDS-PAGE and analyzed by western blot using an
anti-GFP antibody. GFP-ODC* denotes either GFP-ODC or GFP-ODCC441A. (B) Ubext-expressing cells accumulate approximately an equal amount GFPODC in comparison to controls. Protein lysates from cells containing EV, Ub or Ubext co-expressing GFP-ODC were analyzed by SDS-PAGE and western
blot with an anti-GFP antibody and visualized after prolonged exposure (1 hour).
doi:10.1371/journal.pgen.1000382.g003

including the double mutant (UbextK29/48R), impaired the
degradation of the UFD reporter protein Ub-P-bgal (Figure 4C).
Since these data contradict the effects of UbextK29/48R on N-end
rule substrate stability (Figure 4B) and previously published results
with UBB+1 [22], we evaluated another UFD substrate, a
ubiquitin-GFP fusion (UbG76V-GFP). Western blot analysis
revealed that this UFD substrate was also stabilized by Ubext as
well as each UbextKxR mutant, including the double mutant
(Figure 4D). Taken together, these data demonstrate that the
conjugation of Ubext is necessary to cause impaired degradation of
an N-end rule substrate, but mono-Ubext (i.e. UbextK29/48R) can
still impair the degradation of UFD substrates. Based on these
data, we suggest that ubiquitin conjugation to N-end rule
substrates and UFD substrates is different. The degradation
pathways utilized for these two reporters are distinct [3,31,32],
however they typically report on the same degradation competence of the proteasome, although differences have been cited
under certain circumstances [29,44,45]. The observed differences
here could be explained if different proteins interact with the
substrates to perform the ubiquitin conjugation. Perhaps preformed ubiquitin chains are conjugated en masse to N-end rule
substrates but ubiquitin is added sequentially to UFD substrates.
Thus, in the presence of UbextK29/48R the substrates would be
affected differently. Furthermore, this emphasizes that the mode of
ubiquitin conjugation, which remains somewhat of a mystery [46],
may be an important factor in the differential ability of the cells to
cope with one UPS substrate versus another.

modest, yet reproducible, increase in the degradation of UFD
substrate Ub-P-bgal (Figure 5B). This differential stabilization of
the reporters did not occur with different type of mutant ubiquitin,
UbDGG I44A (data not shown). These data suggest that the
interaction of Ubext with other proteins is partially disrupted by
mutating the hydrophobic patch and further supports that Ubext
may have multiple interacting partners to impose the UPS
impairment.

Challenging the UPS Decreases Cellular Tolerance to
Ubext
The UPS is required for the removal of misfolded proteins.
Failure to remove misfolded proteins can lead to aggregation and
have detrimental phenotypic consequences. Since the expression
of Ubext exacerbates UPS defects, we next analyzed whether the
tolerance to misfolded proteins was decreased in cells expressing
Ubext. Canavanine is an arginine analog which becomes
incorporated into newly synthesized proteins and causes misfolding [49]. Serial dilutions of cells expressing Ubext were spotted
onto solid medium containing canavanine. Ubext-expressing cells
showed impaired growth on canavanine containing medium
(Figure 6). This suggests that Ubext interferes with the ability of
the UPS to degrade natural substrates and challenges cell viability
when presented with misfolded proteins.

Expression of Ubext Affects the Cellular Tolerance to Toxic
Aggregates but Does Not Affect Protein Aggregation
We next asked whether misfolded proteins that aggregate would
present an additional challenge to cells expressing Ubext. Using
tools and properties uniquely available in the yeast system, we
sought to determine if Ubext affects protein aggregation by
evaluating both toxic and non-toxic protein aggregates. Since cell
death associated with toxic protein aggregates makes it difficult to
evaluate the potential contribution of UPS dysfunction, the use of
non-toxic aggregates in yeast could provide additional insight as to
the direct effects of Ubext. UBB+1 enhanced the aggregation and
toxicity of a polyglutamine-expanded protein in cultured mammalian cells [24]. To perform similar experiments in our yeast
model, we used a galactose-inducible expanded Huntingtin (Htt)
polyglutamine construct, TOXIC-Q103, which creates a toxic
protein aggregate [50,51]. Cells expressing Ubext could only

Disruption of the Hydrophobic Patch of Ubext Modulates
Proteasomal Impairment of a UFD Substrate
Our data suggest that Ubext might be interacting with multiple
components of the ubiquitin processing pathway, sequestering
proteins required for efficient degradation of proteasome target
substrates. Ubiquitin contains a hydrophobic patch (L8, I44 and
V70) that is critical for its interaction with many other proteins and
the proteasome [47,48]. The ubiquitin mutation I44A disrupts the
hydrophobic patch and this mutant fails to interact with some of its
partner proteins [48]. We created a UbextI44A mutant and tested
whether its expression caused UPS impairment. Cells expressing
UbextI44A still stabilized the N-end rule substrate, R-bgal
(Figure 5A). However, expression of UbextI44A resulted in a
PLoS Genetics | www.plosgenetics.org
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Figure 4. Ubiquitin conjugation of Ubext is required for stabilization of N-end rule but not UFD substrates. (A) Lysines 29 and 48 are
required for ubiquitin conjugation to Ubext. Protein lysate from cells containing empty vector (EV), Ub, Ubext, or UbextKxR were analyzed by SDS-PAGE
and western blot using an anti-ubiquitin antibody. The black arrowhead indicates mono-ubiquitin. The grey arrow points to Ubext. Black arrows
represent conjugated Ubext. Pgk1p was probed to assess protein loading (lower). (B) The conjugation of Ubext is necessary for the impaired
degradation of the N-end rule substrate R-bgal. Cells containing EV, Ub, Ubext, or UbextKxR mutants were transformed with pGalUb-R-LacZ and
analyzed by bgal activity assay. The asterisk (*) denotes statistical significance between Ubext and EV (p = 0.0239). The cross (+) indicates statistical
significance between Ubext and UbextK29/48R (p = 0.032). There is no statistically significant difference between Ubext and UbextK11R (p = 0.1602).
Lower: Corresponding bgal protein levels from the lysates used in the bgal activity assay were detected by SDS-PAGE and western blot using an antibgal antibody. (C) Ubiquitin conjugation of Ubext is not necessary for the impaired degradation of the UFD substrate Ub-P-bgal. Cells containing EV,
Ub, Ubext, or UbextKxR mutants were transformed with pGalUb-P-LacZ and analyzed by bgal activity assay. The asterisk (*) denotes statistical
significance between Ubext and EV (p = 0.0055). There is no statistically significant difference between Ubext and UbextK48/29R (p = 0.4558). (D) Ubextubiquitin conjugation is not necessary to impair the degradation of a second UFD substrate, UbG76V-GFP. Cells containing EV, Ub, Ubext, or UbextKxR
mutants were transformed with UbG76V-GFP and analyzed by SDS-PAGE and western blot using an anti-GFP antibody. The blot was reprobed for
Pgk1p as a loading control.
doi:10.1371/journal.pgen.1000382.g004

Figure 5. Mutation of the Ubext hydrophobic patch (I44A) moderately affects proteasomal impairment. (A) UbextI44A still inhibits N-end
rule substrate degradation. Cells containing pGal-Ub-R-LacZ were transformed with empty vector (EV), Ub, Ubext or UbextI44A (I44A) and the stability
of R-bgal was measured by bgal activity assay. (B) UbextI44A moderately enhances the degradation of a UFD substrate. Cells containing pGal-Ub-PLacZ were transformed with EV, Ub, Ubext or UbextI44A (I44A) and the stability of Ub-P-bgal was measured by bgal activity assay. The asterisk (*)
indicates statistical significance between Ubext and UbextI44A (p = 0.0007).
doi:10.1371/journal.pgen.1000382.g005

alleviating the UPS impairment by altering Ubext protein
interactions relieved the enhanced toxicity.
To determine whether Ubext expression might affect the
aggregates themselves, we imaged a non-toxic version of a
polyglutamine-expanded Htt protein fused to GFP (HttQ103GFP) [52]. Evaluation of these protein aggregates eliminates the
complication of cell death associated with toxic aggregates.
Previous studies have demonstrated that genetic manipulations,
such as altering chaperone levels, can change the abundance and
pattern of polyglutamine-GFP aggregates in cells [53]. Thus, we
tested whether UPS dysfunction caused by the expression of Ubext
would change the aggregate distribution. Neither the abundance
nor the pattern of HttQ103-GFP aggregates was altered in cells
expressing Ubext (Figure 7B). Thus, although the expression of
Ubext did enhance the cellular susceptibility to toxic aggregates, it
did not grossly alter the formation or maintenance of non-toxic
polyglutamine protein aggregates.
One mechanism by which Ubext could be enhancing the toxicity
of TOXIC-Q103 could involve stabilization of the protein, as the
level of expression directly correlates to the amount of toxicity.

tolerate a very low amount of TOXIC-Q103, and even with
minimal induction, Ubext-expressing cells grew much worse in
comparison to control cells (Figure 7A). Interestingly, the
expression of UbextI44A did not result in the same enhanced
protein aggregate toxicity (data not shown). Thus, partially

Figure 6. Ubext expression increases cellular sensitivity to
misfolded proteins. Ubext-expressing cells cannot tolerate excess
misfolded proteins generated by the incorporation of canavanine. Serial
dilutions of cells containing EV, Ub, or Ubext were spotted onto selective
medium and selective medium containing 400 mM canavanine.
doi:10.1371/journal.pgen.1000382.g006
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Figure 7. Ubext expression does enhance the toxicity of polyglutamine expanded protein but does not affect protein aggregation.
(A) Cells containing empty vector (EV), Ub, or Ubext were transformed with a galactose-inducible TOXIC-Q103 construct, which induces cell death in
the presence of galactose. Serial dilutions of transformants were spotted onto selective medium (uninduced) and selective media containing either
0.1% or 0.3% galactose. (B) Pre-existing non-toxic HttQ103-GFP aggregates were not altered in the presence of Ubext. Cells transformed with nontoxic HttQ103-GFP and EV or Ubext were analyzed by fluorescence microscopy. The abundance and pattern of aggregates (dots) was evaluated as
described in Materials and Methods using three independent cultures for each sample. Data are expressed as a percentage of the total cells
containing aggregates. (C) TOXIC-Q103 protein is not stabilized in the presence of Ubext. Cells expressing TOXIC-Q103 in the absence (EV) or presence
of Ubext were treated with cycloheximide and harvested at the indicated times post translational shut off (in minutes). Cell lysates were analyzed by
western blot for the expression of TOXIC-Q103, (which is CFP tagged) using an anti-GFP antibody. Relative protein abundance was quantified as a
ratio of the total (below). The membrane was reprobed with an anti-Pgk1 antibody to show protein loading. (D) TOXIC-Q103 protein aggregates do
not cause proteasomal impairment. pGal-Ub-P-LacZ containing cells with and without Ubext were transformed with galactose-inducible Q25 or
TOXIC-Q103 constructs. The transformants were grown in selective medium containing galactose for 24 hours and the stability of the Ub-P-bgal
substrate was measured by bgal activity assay.
doi:10.1371/journal.pgen.1000382.g007

The stability of TOXIC-Q103 protein was evaluated from cells
expressing Ubext after protein translation was inhibited by
cycloheximide. No drastic stabilization of TOXIC-Q103 protein
was apparent in cells expressing Ubext (Figure 7C).
We next asked whether the TOXIC-Q103 aggregates themselves caused UPS impairment. The stability of the UPS reporter
protein, Ub-P-bgal, was monitored in cells containing TOXICQ103 aggregates in comparison to a non-pathological polyQ25
protein. No stabilization of the reporter was observed in cells
harboring the toxic aggregates (Figure 7D). In addition, the UPS
impairment caused by Ubext was not further increased by the
presence of TOXIC-Q103 (Figure 7D). Thus, the enhanced
toxicity of TOXIC-Q103 caused by Ubext is not due to additive
effects on UPS impairment.

death by unknown mechanisms, analyzing the Sup35p aggregates
in [PSI+] cells provides a unique opportunity to dissect the
contributions of the toxic protein aggregates and UPS dysfunction.
To evaluate the effects of UPS dysfunction on toxic protein
aggregates, [PSI+] cells harboring a copper-inducible SUP35 were
transformed with Ubext and assayed for cell viability (Figure 8A).
Ubext-expressing [PSI+] cells were more susceptible to the over
expression of Sup35p (Figure 8A, red box). The expression of Ubext
did not increase basal levels of Sup35p, as determined by SDSPAGE and western blot analysis (data not shown). Intriguingly, the
expression of a different mutant ubiquitin protein, which caused
UPS impairment similar to Ubext (data not shown), UbDGG, did
not enhance the toxicity of Sup35p over expression to the same
extent (Figure 8A, compare fourth row to sixth row). These results
show that Ubext enhances the toxicity of protein aggregates by a
mechanism that cannot be solely attributed to its effects on UPS
impairment, since UbDGG did not have the same effect.
Furthermore, the hydrophobic domain mutant, UbextI44A, did
not result in the same sensitivity to over expressed Sup35p in
[PSI+] cells (Figure 8A). This suggests that the mechanism by
which Ubext enhances the toxicity of protein aggregates requires
interactions with other proteins via the hydrophobic domain.
We evaluated whether the aggregation of Sup35 is altered by
the expression of Ubext. A previous study demonstrated that
altering ubiquitin levels by either increasing the expression of
ubiquitin or preventing its recycling caused an increase in the
formation of the [PSI+] prion [61]. Furthermore, deletion of a
ubiquitin conjugating enzyme also enhanced [PSI+] induction
[62]. Thus, there is genetic precedence for perturbations of the
UPS affecting prion protein aggregation. We asked whether the
presence of Ubext would alter the spontaneous formation of
aggregated Sup35p and change cells from [psi2] to [PSI+]. We did
not observe a change in the spontaneous conversion rate (data not
shown), which we have measured to be ,1 in 105 in our strain
[63]. We next evaluated the induction of the [PSI+] prion state in
the presence and absence of Ubext by over expressing Sup35p in
[psi2] cells. Since Ubext perturbs the UPS, one might predict an
effect on the induction of protein aggregation. To the contrary, the
expression of Ubext did not enhance the induction of [PSI+]
(Figure 8B).

Enhanced Cellular Toxicity Is Observed with a Second
Toxic Protein
To evaluate the generality of the effects of Ubext on the
phenotypic response to toxic protein aggregates, we used a yeast
prion protein. Prion proteins in yeast form ordered aggregates that
are not harmful to the cells [54–56]. Sup35p, an essential
translation termination factor, is the protein determinant of the
yeast prion [PSI+] [55]. The aggregated prion state of Sup35p,
[PSI+], causes read through of stop codons in translated mRNAs
(nonsense suppression). The percentage of read through is low and
generally has no deleterious effects to cells grown in rich medium
[54]. The presence of the [PSI+] prion can be monitored in a
strain carrying an ade1-14 mutant allele with a premature stop
codon [57]. In [psi2] cells, Sup35p is soluble and functional, and
translation is terminated at the premature stop codon in ade1-14.
Thus, [psi2] ade1-14 cells cannot grow on medium lacking
adenine and when grown on rich medium they appear red due to
the accumulation of an intermediate in the adenine biosynthetic
pathway. Conversely, aggregated Sup35p in [PSI+] cells limits the
amount of functional Sup35p, thereby causing nonsense suppression of the ade1-14 premature stop codon and translation of fulllength Ade1 protein. These cells are adenine prototrophs and
appear white on rich medium. As such, one can evaluate the
functional state of Sup35p as it relates to protein aggregation by
monitoring the color of the yeast colony. Cells can be maintained
stably as [psi2], but they can be induced to become [PSI+] by over
expressing the Sup35 protein.
The [PSI+] prion state is not toxic, however, over expression of
Sup35p in [PSI+] cells inhibits cell growth due to the lack of
sufficient translation termination [58–60]. As one would expect,
the over expression of Sup35p is not toxic to [psi2] cells. Thus, the
toxicity results from too much aggregation of Sup35p in the prion
state. These toxic aggregates provide a means to assess the effects
of aggregation of a protein of known function in combination with
UPS dysfunction. Since most toxic protein aggregates cause cell
PLoS Genetics | www.plosgenetics.org

Expression of Ubext Does Not Cause a Stress Response
The enhanced toxicity of protein aggregates caused by Ubext
could be the result of a general stress response elicited in cells
expressing Ubext. The expression of a heat shock element (HSE)LacZ reporter fusion was evaluated in Ubext-expressing cells and no
increase in transcription from the HSE promoter at 30uC or at a
sub-lethal heat stress of 37uC was observed (data not shown). We
next asked whether the presence of Ubext increased the translation
of a stress-inducible heat shock protein. Protein lysate from Ubext10
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Figure 8. Expression of Ubext enhances the susceptibility of cells to toxic Sup35p aggregates but does not affect Sup35p
aggregation. (A) [PSI+] cells expressing Ubext show reduced cell viability with lower induction of Sup35p. [PSI+] cells containing empty vector (EV),
Ubext, UbDGG, or UbextI44A were transformed with a copper-inducible SUP35 or EV and analyzed for growth by spotting serial dilutions onto selective
media containing 0, 50, or 100 mM CuSO4. At 300 mM CuSO4, [PSI+] cells over expressing Sup35p alone are not viable (not shown). (B) Prion
conversion or induction was not enhanced in cells expressing Ubext. [psi2] cells expressing pSup35 or the control (EV) were transformed with empty
vector (EV), Ub or Ubext and were analyzed for [PSI+] prion formation by monitoring colony color (the appearance of pink colonies). The graph
represents the average of three independent cultures in which approximately 2,000 colonies per culture were evaluated for conversion. (C) Hsp104
protein levels are not enhanced in Ubext-expressing cells. Protein lysate from cells containing EV, Ub, or Ubext were subject to SDS-PAGE and western
blot using an anti-Hsp104 antibody. Pgk1p expression was analyzed as a loading control. (D) The expression of Ubext did not alter cell survival in the
presence of oxidative stress. Cells containing EV, Ub, or Ubext were treated with increasing concentrations of hydrogen peroxide (H2O2) and the
number of viable cells was graphed as a percentage of the untreated. (E) The C-terminal domain of Sup35p (CTD) rescued the enhance susceptibility
caused by Ubext in [PSI+] cells over expressing Sup35p. Upper: [PSI+]-mediated nonsense suppression is alleviated by expression of the CTD. [PSI+]
cells containing EV show more nonsense suppression (the colony color is light pink). However, [PSI+] cells expressing the CTD display efficient
translation termination and the colonies are red. Lower: [PSI+] cells expressing Ubext in addition to excess Sup35p (induced by 50 mM copper) are
rescued from death by the expression of the CTD. (F) Sup35 protein aggregates were not altered by the presence of Ubext. Sup35p aggregates in
strong [PSI+] ([PSI+]) and a weak strain variant of [PSI+] (w[PSI+]) were analyzed by SDD-AGE. The difference in Sup35p aggregate size of these prion
strain variants can be appreciated by this method (compare [PSI+] to w[PSI+]). Sup35p aggregates from cells expressing excess Sup35p (OE Sup35p)
and expressing Ub, Ubext, UbDGG or containing an EV control were analyzed by SDD-AGE and western blot with an anti-Sup35 antibody.
doi:10.1371/journal.pgen.1000382.g008

UbDGG. One possible explanation for the enhanced toxicity in the
presence of Ubext could relate to a change in the degradation of
misfolded Sup35p. As such, we asked whether Ubext was promoting
the accumulation of ubiquitinated-Sup35p. We reprobed the SDDAGE membrane with an anti-ubiquitin antibody but did not find
any ubiquitinated Sup35p by this approach. In additional attempts
to look for ubiquitination of Sup35p, we purified Sup35 aggregates
[68] but again were unable to detect any ubiquitinated Sup35
protein (data not shown). Other researchers have also noted an
inability to identify ubiquitinated-Sup35p [61,62]. Thus, we
conclude that although Ubext affects the ability of cells to tolerate
toxic Sup35p over expression, it is unlikely a direct consequence of
blocking the ubiquitination and degradation of Sup35p.
We also evaluated whether the polyglutamine-expanded Htt
proteins are ubiquitinated. We were unable to detect ubiquitinated
polyglutamine protein in yeast by immunoprecipitation, SDD-AGE
or immunofluorescence (data not shown). The inability to find
ubiquitinated polyglutamine protein has also been noted previously
[52,69,70]. Therefore, as with toxic Sup35p, Ubext is affecting the
tolerance to TOXIC-Q103 aggregates by an indirect means.
How could Ubext be affecting the toxicity of protein aggregates
if those proteins are not subject to ubiquitination and degradation
by the UPS? One possible explanation of the effects of Ubext on
protein aggregate toxicity could be due to a change in the ability to
efficiently sequester the toxic proteins into large aggregates
(Figure 9). A toxic polyglutamine protein expressed in yeast was
rendered non-toxic when sequestered into a single, large
aggresome-like structure [70]. Furthermore, a non-toxic polyglutamine protein, which localizes to an aggresome-like structure,
became dispersed in ubiquitination-deficient cells. We hypothesize
that Ubext alters the localization of toxic proteins into the large
aggregate structures due to its effects on UPS function. The
enhanced toxicity could be the consequence of a reduced ability to
sequester toxic soluble oligomer species (Figure 9).

expressing cells and control cells showed similar levels of Hsp104p
(Figure 8C), a stress-responsive chaperone. Finally, we tested the
tolerance of the cells to oxidative stress. Cells challenged with
hydrogen peroxide showed no change in survival in the presence
of Ubext (Figure 8D). These results suggest that Ubext expression in
yeast neither induces a general stress response nor preconditions
the yeast to exogenous insult. Therefore, the enhanced susceptibility of Ubext-expressing cells to toxic aggregates is not likely the
result of Ubext inducing a general stress.

Restoration of Translation Termination Rescues
Enhanced Toxicity Caused by Ubext
Overcoming the enhanced protein aggregate toxicity induced
by Ubext expression could shed light on the mechanism by which
Ubext exerts its affects. In attempts to alleviate the Ubext-enhanced
aggregate toxicity we conducted a genomic over expression screen
using the toxicity caused by over expression of Sup35p in [PSI+]
cells. We uncovered two rescuing factors, HSP104 and SUP45.
Both of these proteins alleviate the toxicity by affecting Sup35p
aggregation and the associated phenotypic readout. Over
expression of Hsp104p affects the Sup35p aggregates [64] and
Sup45p can sequester Sup35p away from the aggregates [65]. To
verify that the enhanced protein aggregate toxicity in the presence
of Ubext can be overcome by altering nonsense suppression, we
over expressed the C-terminal domain (CTD) of Sup35p, which is
sufficient for translation termination but cannot aggregate and
form or join the prion state [58,66]. We found that the expression
of the CTD not only restored translation termination of [PSI+]
cells (Figure 8E, upper), but also alleviated the enhanced toxicity
caused by the expression of Ubext (Figure 8E, lower). These results
demonstrate that alleviating the primary deficit in the cells (i.e. the
effects of [PSI+]) is sufficient to overcome toxicity even in the
presence of a modifier (Ubext).

Model to Explain Cellular Affects of Ubext on Aggregate
Toxicity

Enhancing Protein Aggregate Toxicity by Increasing the
Burden on the UPS

ext

We next asked whether Ub
affected the toxic Sup35p
aggregates, since the enhanced cellular toxicity caused by Ubext
and excess Sup35p is [PSI+]-dependent. We assayed Sup35p
aggregates by semi-denaturing detergent agarose gel electrophoresis
(SDD-AGE) [67]. This technique allows large protein aggregates to
migrate into the gel and can resolve aggregates of different sizes, as
demonstrated by a strain variant of [PSI+] (weak [PSI+]), which
harbors larger Sup35p aggregates than our [PSI+] starting strain
(Figure 8F). We observed no change in the size of Sup35p aggregates
from cells over expressing Sup35p in combination with Ubext or
PLoS Genetics | www.plosgenetics.org

Based on our hypothesis, we predict that protein aggregate
toxicity can be affected by perturbations in ubiquitination or by
overwhelming the UPS in general. We took advantage of a
temperature-sensitive ubiquitin activating enzyme (E1) mutant
(uba1-204) [71] to evaluate the effect of an overall reduction in
ubiquitination on the phenotypic response to TOXIC-Q103
aggregates. UBA1 is an essential gene responsible for the first step
of the ubiquitination cascade. At the restrictive temperature, the
uba1-204 mutant limits substrate ubiquitination. A recent study
12
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Figure 9. Model for Ubext affects on toxic protein aggregates. We propose that enhanced protein aggregate toxicity in Ubext-expressing cells
is due to the inability of misfolded amyloidogenic proteins to be properly sequestered. The small soluble oligomers are more toxic than the large
insoluble protein aggregates. UPS impairment caused by the expression of Ubext may hinder the rapid sequestration or retention of toxic oligomers
into large protein aggregates.
doi:10.1371/journal.pgen.1000382.g009

PVDF and visualized by western blot. The amount of soluble
protein as normalized to total protein was determined by
densitometry (Figure 10D). The amount of soluble TOXICQ103 was higher in Ubext-expressing cells than wild type cells.
Thus, the enhanced toxicity of TOXIC-Q103 in Ubext-expressing
cells correlates to an increased pool of soluble protein and supports
the model proposed in Figure 9.

demonstrated that polyglutamine protein aggregate patterns were
altered in cells expressing the uba1-204 mutant [70]. uba1-204 cells
expressing TOXIC-Q103 or the control (Q25) were grown in
inducing conditions at the permissive (30uC) and restrictive
temperatures (32uC) and colony survival was measured
(Figure 10A). Cells expressing TOXIC-Q103 showed approximately 50% survival in comparison to those expressing Q25, and
this survival was further decreased in conditions of limiting
ubiquitination (i.e. 32uC). To directly compare the affect of Ubext
expression on the TOXIC-Q103 aggregates, we measured colony
survival as performed above. Cells harboring TOXIC-Q103
aggregates in the presence of Ubext allowed for only a 7% survival
in comparison to TOXIC-Q103 aggregates alone (56% survival).
Thus, Ubext is a more potent modifier of toxic protein aggregates
than perturbations in ubiquitination.
Since decreased ubiquitination had an affect on the protein
aggregate toxicity, we asked if protein aggregate toxicity could also
be enhanced by increasing the burden on the UPS. We measured
the viability of cells expressing TOXIC-Q103 or over expressing
Sup35p in the presence of canavanine. Serial dilutions of cells
expressing Q25 and TOXIC-Q103 were spotted onto inducing
media containing canavanine. The effects of the glutamine
expansion on cell viability can be seen on inducing plates and in
the presence of a UPS burden (canavanine) the toxicity is
enhanced (Figure 10B). Over expressed Sup35p in [PSI+] cells
also shows toxicity and in the presence of canavanine the toxicity is
slightly enhanced (Figure 10C). However, canavanine is less potent
at enhancing the toxicity of over expressed Sup35p in comparison
to the effect of Ubext (Figure 8A). Nonetheless, perturbations to the
UPS in general do appear to enhance protein aggregate toxicity.
We propose that this is due to a change in efficient sequestration of
toxic proteins into insoluble aggregates (Figure 9).
Since Ubext enhanced the toxicity of TOXIC-Q103, we tested
whether Ubext-containing cells were compromised in their ability
to sequester or retain TOXIC-Q103 in the insoluble aggregates.
Protein lysates from Ubext and controls cells (EV) were subjected to
high speed ultracentrifugation and analyzed to determine whether
Ubext influences the amount of soluble TOXIC-Q103. Serial
dilutions of the total and resulting soluble fraction were applied to
PLoS Genetics | www.plosgenetics.org

Ubext Alters Ubiquitination Patterns
Since altered ubiquitination affected the distribution of
expanded polyglutamine proteins [70] and enhanced the cellular
susceptibility to toxic polyglutamine aggregates (Figure 10A), we
asked whether Ubext has a direct effect on the ubiquitination of
proteasome substrates. In light of the fact that the toxic protein
aggregates are not ubiquitinated, we evaluated the ubiquitination
pattern of the UPS reporters. To compare the ubiquitination of
these constructs with and without the expression of Ubext, we
utilized a temperature-sensitive proteasome mutant strain (pre1-1
pre2-2) [28]. This strain is defective in proteolysis and when grown
at the restrictive temperature, R-bgal and Ub-P-bgal accumulate
(Figure 11A). Striking substrate ubiquitination can be observed in
pre1-1 pre2-2 cells expressing Ubext and control cells after IP. When
we compared the R-bgal substrate ubiquitination in EV and
Ubext-containing cells, we did not discern any difference in the
ubiquitination pattern (Figure 11A). However, a subtle yet
reproducible ubiquitination pattern difference was seen with the
Ub-P-bgal substrate (Figure 11B). Three independent IP experiments are shown and two ubiquitinated-bgal bands appear in
control cells (EV) which are absent or greatly reduced in Ubextexpressing cells. The altered ubiquitination pattern of some UPS
substrates in the presence of Ubext could change the ability of these
proteins to be processed by the proteasome. Furthermore, such
changes could be an important modifier of the cellular effects of
toxic protein aggregates.

Discussion
We created a novel model of UBB+1 by constitutively
expressing an analogous mutant ubiquitin protein in yeast to
13
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amount of soluble TOXIC-Q103 protein normalized to the total protein
for each sample and graphed in relative arbitrary units. Three
independent cultures for each sample were analyzed. The asterisk (*)
denotes statistical significance (p = 0.0052).
doi:10.1371/journal.pgen.1000382.g010

investigate the causal relationship between this proteasomal
inhibitor and protein aggregation. We demonstrated that the
Ubext mutant was not functional as ubiquitin and was not
deleterious to the cells. Importantly, the expression of Ubext in
yeast caused impairment of the UPS. Since proteasome dysfunction can lead to protein aggregation, we were intrigued that the
presence of Ubext served to neither induce nor alter non-toxic
protein aggregates in yeast. However, the expression of Ubext
rendered the cells more susceptible to toxic protein aggregates,
and this could not be attributed to an increase in general stress
elicited by Ubext. We propose that the reduced UPS functionality
and altered ubiquitination of UPS substrates in Ubext-expressing
cells creates an environment in which toxic amyloidogenic proteins
either cannot join or are not maintained as large insoluble
aggregates. As a result, protein aggregate toxicity is enhanced due
to an increase in soluble or oligomeric toxic protein. Thus, this
yeast model system revealed that Ubext is a phenotypic modifier of
toxic protein aggregates. This genetically tractable model provides
a platform to further dissect how UBB+1 affects the cellular
tolerance to toxic protein aggregates.

Figure 10. Protein aggregate toxicity is enhanced by perturbations of the UPS and protein aggregate solubility is
enhanced by Ubext. (A) Limiting ubiquitination also decreases cellular
survival in the presence of TOXIC-Q103. Cellular viability of TOXIC-Q103
(103) or the Q25 control expressed in ts uba1-204 cells was measured at
the permissive temperature (30uC) and a restrictive temperature (32uC).
The graph represents the percentage of viable cells from the inducing
plates compared to cells grown on non-inducing medium. The asterisk
(*) indicates statistical significance between 25 and 103 at 30uC
(p = 0.0007), the cross (+) indicates statistical significance between 25
and 103 at 32uC (p = 0.0003), and the double asterisk (**) indicates
statistical significance between 103 at 30uC and 32uC (p = 0.0068). (B)
Increasing misfolded proteins enhanced toxicity in the presence of
TOXIC-Q103. Cell expressing TOXIC-PQ103 (103) and the Q25 control
(25) were spotted onto inducing medium and inducing medium
containing 200 mM canavanine (Can). (C) The cellular susceptibility of
over expressed Sup35p in [PSI+] cells in the presence of canavanine is
not as detrimental as the co-expression of Ubext. Cells expressing excess
Sup35p (induced with 200 mM CuSO4) were spotted onto plates
containing 400 mM canavanine (Can). Sup35 over expressing cells are
slightly less viable in the presence of 400 mM canavanine. All cells died
at higher concentrations of CuSO4 and canavanine. (D) Cells expressing
Ubext contain more soluble TOXIC-Q103 protein. Cells expressing
TOXIC-Q103 in the presence of Ubext or absence (EV) were lysed and
the soluble protein was analyzed by western blot after high speed
ultracentrifugation. Densitometry was performed to determine the

PLoS Genetics | www.plosgenetics.org

Figure 11. Ubext alters the ubiquitination pattern of a UPS
substrate. (A) R-bgal ubiquitination pattern is not altered in cells
expressing Ubext. pGalUb-R-LacZ was transformed into proteasome
mutant cells (pre1-1 pre2-2) expressing Ubext or EV and R-bgal was
analyzed by immunoprecipitation (IP). Membranes were probed with
anti-bgal and anti-ubiquitin antibodies. Arrow indicates full length bgal
protein. (B) Ub-P-bgal ubiquitination is affected in cells expressing
Ubext. Ub-P-bgal IPs were performed as in A. A subtle but reproducible
difference in ubiquitination pattern was observed. Three independent
IPs are shown. Arrowheads highlight distinct bands present in the EV
lanes that are absent in Ubext lanes.
doi:10.1371/journal.pgen.1000382.g011

14

February 2009 | Volume 5 | Issue 2 | e1000382

Mutant Ubiquitin in Yeast

of the single aggregate when mutated were two ubiquitinassociated proteins. Furthermore, limiting general cellular
ubiquitination by the uba1-204 mutant also disrupted the
formation of the large aggregate [70]. We show that uba1-204
enhanced the cellular toxicity of the toxic polyglutamine
aggregates used in our study (Figure 10A). Taken together, the
data support the proposed model of the effect of Ubext on protein
aggregate toxicity (Figure 9).
Since Ubext causes UPS impairment and a change in
ubiquitination of substrates, this could cause the mis-handling or
redistribution of some ubiquitin-conjugated proteins and hinder
toxic protein aggregates from being rapidly sequestered, resulting
in enhanced cell death (Figure 9). Thus, even though the toxic
protein aggregates may not be substrates of the UPS, perturbations
in the processing of normal UPS substrates may affect cellular
tolerance to toxic aggregates. Our data suggest that all
perturbations in the UPS are not equally potent at altering the
cellular tolerance to toxic aggregates. Therefore, we conclude that
the magnitude of the enhanced protein aggregate toxicity in the
presence of the extended mutant ubiquitin is exceptional. This is
likely due to its interactions with other proteins and supports
further that UBB+1 may be a potent disease modifier.
Since protein conformational disorders result from a combination of cellular perturbations, often including the unknown affects
of aging, then eliminating individual modifiers or enhancers may
prove useful for disease therapy. Obviously, alleviating the primary
causative agent, when known, could prove to be the most
beneficial. For example, when we used the Sup35p toxic aggregate
model we were able to rescue the Ubext-enhanced toxicity by
restoring the loss of function caused by Sup35p sequestration into
aggregates. However, in many protein conformational diseases,
the function of the proteins found in the aggregates and cellular
toxicity is not understood. Therefore, investigating ways to
alleviate the effects of known modifiers represents an important
therapeutic avenue for disease treatment and prevention. The
insight gained by developing a yeast model of UBB+1 has
provided a means to further investigate the role of protein
aggregate compartmentalization in toxicity, which may underlie
some of the effects observed in cells or tissues experiencing chronic
UPS impairment. The identification of UBB+1-interacting
proteins may allow for the elucidation of the mechanism whereby
a natural modifier of UPS function affects cellular tolerance to
toxic protein aggregates.

The mechanism of UPS impairment caused by UBB+1 is not
well understood. We asked whether Ubext causes a reduction in
proteasome activity. Using an unstable ubiquitin-independent
substrate (GFP-ODC) [37], we observed no significant change in
the activity of the proteasome in Ubext-expressing cells. Based on
this result, we suggest that Ubext is not clogging the core of the
proteasome and propose that Ubext is interacting with other
components of the ubiquitin processing cascade or with the
regulatory cap of the proteasome. We hypothesized that disrupting
the interaction of Ubext with component(s) of the ubiquitin
processing pathway would alleviate the proteasomal impairment.
Mutational analysis revealed that ubiquitin conjugation and the
hydrophobic patch affect the extent to which Ubext causes UPS
impairment. Interestingly, the effects were distinct with different
substrates. This supports the idea that Ubext is interacting with
multiple components of the UPS; reduction of its interaction via
the hydrophobic patch or elimination of its ubiquitination
weakened some of the observed effects but not others.
Previous studies have investigated the connection between UPS
dysfunction and protein aggregation, especially in the context of
protein conformational disorders [72]. It remains difficult,
however, to discern the precise nature of the causal relationship
between protein aggregation and proteasomal impairment.
Evidence that UBB+1 and other disease-associated mutations in
the UPS can cause proteasomal impairment and increase protein
aggregation supports the idea that proteasome dysfunction plays a
stimulatory role in protein aggregation. However, in some cases,
such as that with mutant Parkin in familial Parkinson’s Disease,
decreased UPS function is not associated with protein aggregation
[8]. Using non-toxic protein aggregates in yeast, we have
demonstrated that a UBB+1-like protein, Ubext, neither induced
nor changed protein aggregates. Our results provide evidence that
a compromised UPS does not necessarily affect protein aggregation per se but can cause phenotypic effects by decreasing cellular
tolerance to deleterious protein aggregates.
We hypothesize that Ubext is altering the sequestration of
aggregated proteins (Figure 9). Due to the altered substrate
ubiquitination and the general UPS impairment caused by Ubext,
misfolded proteins are not efficiently degraded and somehow
perturb the sequestration of amyloidogenic proteins into the
insoluble aggregates which may have a protective function. How
the UPS functionality plays a role in the ability of the cell to
efficiently sequester non-ubiquitinated proteins remains to be
elucidated. One recent study suggests that different cellular
compartments retain aggregates of ubiquitinated and nonubiquitinated proteins and a reduction in UPS activity can cause
a change in this localization [69]. If proper localization of
aggregated proteins protects the cell from smaller toxic oligomeric
species [73,74], then the inability of toxic oligomers to be
efficiently sequestered would be deleterious (Figure 9). Indeed,
the expression of Ubext resulted in an increase in the relative
amount of soluble TOXIC-Q103 protein (Figure 10D) and the
combination of Ubext and TOXIC-Q103 was more deleterious to
cell survival (Figure 7A). Further evidence to support the idea that
the redistribution of aggregates can lead to cell death comes from a
recent report investigating the nature of the aggregates formed in
response to the expression of expanded polyglutamine protein in
yeast [70]. A single large aggregate, an aggresome-like structure,
was formed by polyglutamine proteins that were not toxic to the
cells. When the large aggregate was unable to form, multiple small
aggregates were observed and the appearance of these correlated
with toxicity. Thus, the single large aggregate appears to be
protective against polyglutamine protein aggregate toxicity.
Among the cellular factors found that could disrupt the formation
PLoS Genetics | www.plosgenetics.org

Materials and Methods
Strains
Yeast strains were grown and manipulated by standard
techniques [75]. Unless otherwise indicated, all yeast strains used
in this study were derivatives of 74-D694 (MATa or MATa ade1-14
trp1-289 his3D-200 ura3-52 leu2-3,112) [64]. The Dubi4 strain was
created by PCR amplification of the antibiotic resistance marker
KanMX4 with primers A and B and subsequent transformation of
the resulting product into 74-D694. For all primer sequences, see
Table 1. The Dubp14 strain was created by PCR amplification of
BY4741 Dubp14 genomic DNA with primers C and D and
subsequent transformation of the resulting product into 74-D694.
The proteasome mutant strain, WCG4-11/22a (MATa his3-11,15
leu2-3,112 ura3 pre1-1 pre2-2) and control strain, WCG4a (MATa
his3-11,15 leu2-3,112 ura3) were a kind gift of P. Coffino [37]. The
74-D694 [PSI+]-inducible prion strain [psi2] [RNQ+] and the
weak [PSI+] strain variant were a kind gift from S. Liebman [76].
A 74-D694 [PSI+] [RNQ+] strain was used in the PQ toxicity
study. The uba1-204 strain was a kind gift from R. Deshaies [71].
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Table 1. Primer sequences.

Code

Used to make (enzyme)

Sequence (59 orientation)

A

ubi4 deletion

GTATTACCCGGCTTCGCGAAAATAGTGAACGTCATAGTATAAGACGATTCATCGATGAATTCGAGCTCG

B

ubi4 deletion

GGGGTATATATAGAGAGGCTCCGGGTTTTGCCACCTTTGAATTCGCCTGCCGTACGCTGCAGGTCGAC

C

ubp14 deletion

CACTTGATGAAATCACAGTGAAAAGCG

D

ubp14 deletion

CGATAGATTTGATCATACACATATAATGC

E

59 Ub (XbaI)

GCT CTA GAA TGC AGA TTT TCG TCA AGA C

F

39 Ubext (BamHI)

CGGGATCCTTAACAAAGATCTGCATACCACCTTAGCCTTAGCACAAGATGTAAGG

G

59 Ub (BamHI)

CGGGATCCATGCAGATTTTCGTCAAGAC

H

39 Ub (SalI)

GCGTCGACTCAACCACCTCTTAGCCTTAG

ext

K11R (BamHI)

CCGGATCCATGCAGATTTTCGTCAAGACTTTGACCGGTAGAACCATAACATTGG

I

59 Ub

J

39Ubext (SalI)

CGGTCGACTTAACAAAGATCTGCATACCACCTTAGCCTTAGCACAAGATGTAAGG

K

59 Ubext K29R*

GAAGGTATCCCTCCAGATCAAC

L

39 Ubext K29R*

CTTGTCTTGAATTcTCGACTTAACGTTGTCGATG

M

59 Ubext K48R*

ACGGTAGAACGCTGTCTG

N

39 Ubext K48R *

CTTCTAGCTGtcTACCGGCAAAG

O

39 Ubext K63R‘

GATGTAAGGTGGACTCCCTCTGAATGTTGTAATC

P

39 Ubext+GG (SalI)

GGCGGTCGACTTAACCACCACAAAGATCTGCATACCAC

Q

39 UbDGG (SalI)

GGCGGTCGACTTATCTTAGCCTTAGCACAAG

R

39 UbextI44A‘

CTTACCGGCAAAGGCCAATCTTTGTTG

S

59 UbextI44A‘

CAACAAAGATTGGCCTTTGCCGGTAAG

*

Used in three-way ligation with cut p423TEF vector.
Used in bridge-PCR and cloned into cut p423TEF vector.
doi:10.1371/journal.pgen.1000382.t001
‘

polyQ103-GFP [52], referred to as HttQ103-GFP in this
manuscript. Toxic polyglutamine aggregation assays employed
p416Gal FLAG103Q-CFP (referred to as TOXIC-Q103) and
p416Gal FLAG25Q-CFP (referred to as Q25) (kind gift M.
Duennwald) [50,51]. For the toxicity assay in [PSI+] cells, Sup35p
was over expressed from a copper inducible promoter.
pRS315Cup-SUP35 was generated by cloning Cup1-SUP35
between XhoI and SacI. pRS316-TEF-CtermSup35 contains only
the C-terminal domain (amino acids 254–685) of Sup35 and was
created by subcloning TEF-CtermSup35 from pRS306TEFCtermSup35 [80] at HindIII and SacI.

Plasmids
All plasmids were created using standard molecular biology
protocols [77] and verified by DNA sequencing. For primer
sequences, refer to Table 1. Where appropriate, the enzyme used
is listed parenthetically. To create p413TEFUbext, ubiquitin was
PCR amplified from 74-D694 genomic DNA using primers E and
F and cloned into p413TEF [78] at XbaI and BamHI. To create
p413TEFUb, ubiquitin was PCR amplified from 74-D694
genomic DNA using primers G and H and cloned into
p413TEF at BamHI and SalI. Ubext was subcloned from
p413TEFUbext to p423TEF and p426TEF at SpeI and BamHI.
Ubiquitin was subcloned from p413TEFUb to p423TEF and
p426TEF at SalI and BamHI. All Ubext amino acid substitutions
(p423TEFUbextK11R, UbextK29R, UbextK48R, UbextK63R,
UbextK29/48R, UbextI44A) were created using either three-way
ligation or bridge PCR into p423TEF using p423TEFUbext as a
template (except for the p423TEFUbextK29/48R mutant which
utilized p423TEFUbextK29R) and following standard molecular
biology techniques [77]. p423TEFUbext+GG was created by PCR
amplification of ubiquitin DNA with primers G and P and cloned
into p423TEF at BamHI and SalI. p423TEFUbDGG was created
by PCR amplification of ubiquitin DNA with primers G and Q
and cloned into p423TEF at BamHI and SalI. The 4xHSE-LacZ
plasmid was a kind gift of S. Lindquist. In vivo UPS functionality
was measured using Ub-X-LacZ reporters: pGal-Ub-M-LacZ,
pGal-Ub-R-LacZ, and pGal-Ub-P-LacZ [30]. The ubiquitinindependent proteasome substrates, p416ADH1GFP-mODC
and p416ADH1GFP-mODCC441A were a kind gift from P.
Coffino [37]. The UBI4promoter-LacZ reporter was a kind gift from
M. Altmann [79]. [PSI+] induction assays used the inducer
plasmid pEMBL Sup2 (referred to as pSup35 in this manuscript)
[58]. Non-toxic polyglutamine aggregation assays used p416GPD
PLoS Genetics | www.plosgenetics.org

Protein Analyses
Protein lysates were analyzed by standard SDS-PAGE. Protein
lysis followed the b-galactosidase assay (see below). The following
antibodies were used: Ubiquitin (PD41) (Santa Cruz sc-8017),
Hsp104 (kind gift of S. Lindquist), GFP (kind gift of M. Linder), bgalactosidase (Promega Z378A), Pgk1 (Molecular probes A6457),
and Sup35 (kind gift of S. Lindquist) [81]. Large Sup35 protein
aggregates were separated by SDD-AGE as previously described
[82] with modifications previously described [63]. Sup35p over
expression was achieved by growing the cultures in 50 mM copper
sulfate overnight. Immunoprecipitations were carried out as
previously described [83] using 5 ml of mouse anti-b-galactosidase.
TOXIC-Q103 protein stabilization was measured after a six hour
induction (2% galactose and 1% raffinose containing media) in the
presence of 0.5 mg/ml cycloheximide in cultures with equal
numbers of cells.
The relative amount of TOXIC-Q103 soluble protein was
determined by slot blot. Cells containing TOXIC-Q103 and either
EV or Ubext were grown overnight in selective medium, washed in
inducing medium containing 2% galactose/1% raffinose and
16
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induced for 14–16 hours. Cells were harvested and lysed with glass
beads in PEB (250 mM Tris HCl pH 7.5, 50 mM KCl, 10 mM
MgCl2, 1 mM EDTA, 10% glycerol, 10 mM PMSF, 5 mg/ml
Aprotinin, Roche Protease cocktail inhibitor (Roche)). Equal
protein (100 mg) from EV and Ubext-containing cells was subjected
to ultracentrifugation (80,000 rpm for 30 minutes at 4uC). Serial
dilutions of the supernatant and total fractions (diluted 1/10) were
applied to activated PVDF and probed with an anti-GFP
antibody. The supernatant fraction and corresponding total
fractions were quantified using Image J software and graphed as
normalized arbitrary units.

treated sample. Error bars represent the standard deviation of
three independent cultures for each construct in each condition.
Proteasome mutant strain synthetic lethality. The
proteasome mutant strain (WCG11-22a) and control strain
(WCGa) containing p423TEF EV, p423TEF Ub or p423TEF
Ubext were grown overnight in selective medium at 30uC and fivefold serial dilutions of the cultures were spotted on selective
medium and grown at 30uC and 37uC.
Canavanine treatment. Cells containing p423TEF EV,
p423TEF Ub or p423TEF Ubext were grown overnight in
selective medium. Five fold serial dilutions of cultures were
spotted onto selective medium containing 200 or 400 mM
canavanine. Cells containing TOXIC-Q103, Q25, pRS315EV
or pRS315Cup-Sup35 were grown overnight in selective medium.
Five fold serial dilutions of cultures were spotted onto selective
media containing the indicated amount of copper sulfate and
canavanine or galactose and canavanine.
[PSI+] induction. Three independent cultures of 74-D694
[psi2] [RNQ+] cells containing pEMBL Sup2 [58] in addition to
p423TEF EV, p423TEF Ub or p423TEF Ubext were grown
overnight in selective medium to an OD600,1.5. The cultures
were diluted and plated on YPD, where ,2,000 colonies were
scored for prion induction. Error bars represent the standard
deviation.
Toxic polyglutamine aggregation. [PSI+] [RNQ+] cells
containing p416Gal FLAG103Q CFP or p416Gal FLAG25Q
CFP [50,51] and p423TEF EV, p423TEF Ub, or p423TEF Ubext
were grown overnight in selective medium. The cultures were
diluted five-fold and spotted on selective media containing 0.1% or
0.3% galactose with 1% raffinose.
Toxic Sup35p over expression. 74-D694 [PSI+] [RNQ+]
cells containing pRS315Cup-EV or pRS315Cup-Sup35 and
p423TEF EV, p423TEF Ubext, p423TEF UbDGG or p423TEF
UbextI44A were grown overnight in selective medium. Cultures
were diluted five-fold and spotted on selective medium containing
50 mM or 100 mM copper sulfate. pRS315TEF-CtermSup35 or
control pRS315 EV were transformed into Ubext-expressing cells
containing pRS315Cup-Sup35 and plated on selective medium
containing 50 mM copper sulfate.

b-Galactosidase Assays
UPS functionality was determined by the degradation of UbLacZ fusions [30] using Galacto-lightTM (Applied Biosystems).
Cells containing pGal-Ub-M-LacZ, pGal-Ub-R-LacZ and pGalUb-P-LacZ were grown in selective medium for 24 hours. The
cultures were washed three times in selective medium containing
2% galactose / 1% raffinose and grown overnight in the 2%
galactose / 1% raffinose. The cultures were harvested and lysed in
Galacto-light Lysis Solution using glass beads. Cell lysate was precleared for 30 seconds at 6,000 rpm at 4uC. In a flat bottom,
black-sided 96-well dish, 70 ml of Galacto Reaction Buffer was
added to 10 ml of protein lysate and incubated for 60 minutes at
room temperature. Luminescence was read immediately after the
addition of 100 ml of Light Emission Accelerator. Luminescence
values were normalized to protein concentration as determined by
Bradford reagent (BioRad). Error bars in all bgal activity assays
represent the standard deviation from three independent cultures
for each sample. The TOXIC-Q103 protein bgal activity assay
was conducted as described above using a TRP1 version of pGalUb-P-LacZ (subcloned into p424Gal vector) with a 24 hour
induction. All statistical analyses were conducted using Student’s
T-Test.

Microscopy
Polyglutamine aggregation was monitored by GFP fluorescence
in a 74-D694 [PSI+] [RNQ+] strain background. Three independent samples of mid-log phase cells containing p416GPD
polyQ103-GFP [52] and p423TEF EV or p423TEF Ubext were
visualized. Individual fluorescent cells were evaluated for a single
aggregate, few aggregates (2–3 per cell) or multiple aggregates
(greater than 3 aggregates per cell) as previously described [53].
Approximately 200 cells were analyzed for each sample in
triplicate. Error bars represent the standard deviation.
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